Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Reports Strong Q4 2025 Results and Provides 2026 Guidance
Summary
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the fourth quarter and full year 2025, with total revenue of $3.19 billion for Q4 2025, a 10% increase from Q4 2024, and $12.0 billion for the full year 2025, a 9% increase from 2024. The company provided full year 2026 financial guidance, expecting total revenue between $12.95 billion and $13.1 billion. Key highlights included positive clinical trial results for drugs such as ALYFTREK, CASGEVY, and JOURNAVX, and progress in the R&D pipeline across various therapeutic areas.
Profitelligence Alerts
Get alerts for VRTX
Be first to know when Vertex Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Official SEC Documents
Advertisement